Ulipristal acetate versus conventional management of heavy menstrual bleeding (HMB; including uterine fibroids): a randomised controlled trial and exploration of mechanism of action (UCON trial)

Trial Profile

Ulipristal acetate versus conventional management of heavy menstrual bleeding (HMB; including uterine fibroids): a randomised controlled trial and exploration of mechanism of action (UCON trial)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 03 May 2017

At a glance

  • Drugs Ulipristal (Primary) ; Levonorgestrel
  • Indications Menstruation disorders
  • Focus Therapeutic Use
  • Acronyms UCON
  • Most Recent Events

    • 12 Apr 2017 Status changed from recruiting to active, no longer recruiting.
    • 04 Nov 2015 Accrual till date is 5% according to United Kingdom Clinical Research Network record.
    • 04 Oct 2015 Accrual till date is 4% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top